Weekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes Innovation

episode

tHEORetically Speaking not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from tHEORetically Speaking

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap 11 min · 13 Jul 2026

All episodes from tHEORetically Speaking →

Report any issue

Source

Recorded07 Nov 2025

Publisherfeeds.buzzsprout.com

Handlerec:11539508

Show notes

This week’s tHEORetically Speaking News Roundup covers the sudden resignation of the FDA’s top drug chief amid controversy, Novo Nordisk’s sweeping restructuring and strategic reset in the obesity and diabetes markets, and a groundbreaking data partnership between ŌURA and Tidepool driving innovation in diabetes research. We also explore how rising healthcare costs threaten the future of clinical trial diversity. Tune in for this concise recap of these pivotal industry updates!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.